Mandate

VINGE ADVISES FORTUM with SALE OF Fortum Distribution

March 16, 2015

Fortum and a consortium consisting of the First Swedish National Pension Fund (12.5%), the Third Swedish National Pension Fund (20%) and Folksam (17.5%) as well as the international infrastructure investment company, Borealis Infrastructure Management Inc. (50%) signed a purchase agreement in respect of Fortum Distribution AB, a company which constitutes Fortum’s electricity network operation in Sweden. 

The total purchase price is EUR 6.6 billion (equivalent to approximately SEK 60.6 billion) on a cash free/debt free basis. Fortum anticipates that the transaction will be completed during the second quarter of 2015, provided that the requisite regulatory approvals and the agreement’s customary conditions are fulfilled. Fortum anticipates reporting a non-recurring revenue item for the second quarter of 2015 of approximately EUR 4.4 billion, equivalent to approximately EUR 5 per share.

Vinge’s team consisted of responsible partner Johan Göthberg together with associates Gustav Jönsson and Andrea Jägerstedt (M&A), partners Jonas Eklund and Carl Johan af Petersens and Fredrik Lundblom as well as associates Emilie Håkansson, Helena Wanhainen and Johan Cederblad (regulatory). 

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026